Lupin gets USFDA’s nod for Clomipramine Hydrochloride Capsules

26 Nov 2018 Evaluate

Lupin has received approval for its Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg from the United States Food and Drug Administration (USFDA) to market a generic version of SpecGx LLC's Anafranil Capsules, 25 mg, 50 mg, and 75 mg.

Lupin's Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg is the generic version of SpecGx LLC's Anafranil Capsules, 25 mg, 50 mg, and 75 mg. It is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).

Anafranil Capsules, 25 mg, 50 mg, and 75 mg had annual sales of approximately $109.6 million in the US (IQVIA MAT September 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2061.50 -36.15 (-1.72%)
08-Dec-2025 15:46 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1790.05
Dr. Reddys Lab 1272.70
Cipla 1498.90
Zydus Lifesciences 924.35
Lupin 2061.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×